ClinicalTrials.gg
CompletedNCT03472014Updated Aug 19, 2020Results posted

Special Access Program IMVAMUNE®

A Phase 4 interventional study of IMVAMUNE® in Vaccination, sponsored by Bavarian Nordic. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by Bavarian Nordic · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 7 years 10 months after the study started (first participant enrolled Apr 2010, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of replicating vaccinia virus

02

Conditions studied

  • Vaccination
03

In context

Lead sponsor

Bavarian Nordic is the lead sponsor of 58 studies on the registry; 2 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, aged 18-65 years, who will work with or in the vicinity of a replicating vaccinia virus and who volunteer for the program. Subjects may be vaccinia-naïve or vaccinia-experienced.
  • Women of (WOCBP) must have a negative urine pregnancy test within 48 hours prior to vaccination.
  • WOCBP must have used an acceptable method of for at least 30 days prior to the first vaccination and must agree to use an acceptable method of contraception during the vaccination period until at least 28 days after the last vaccination. A woman is considered of child-bearing potential unless or surgically sterilized. (Acceptable contraception methods are restricted to barrier contraceptives which include Food and Drug Administration (FDA)-approved spermicides, intrauterine contraceptive devices, or licensed hormonal products.)
  • Read, signed and dated Form.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women.
  • Uncontrolled serious infection i.e., not responding to antimicrobial therapy.
  • History of or active disease. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
  • Known or suspected impairment of immunologic function including, but not limited to, liver disease; uncontrolled diabetes mellitus; moderate to severe kidney impairment or post organ transplant subjects.
  • History of , other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure.
  • History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or , uncontrolled high blood pressure, or any other heart condition under the care of a doctor.
  • History of allergies or reactions to eggs, egg products, or gentamycin.
  • Having received any vaccinations or planned vaccinations with a within 28 days or a killed vaccine within 14 days prior to or after IMVAMUNE®vaccination.
  • Chronic administration (defined as more than 6 days) of systemic within 30 days of the first planned vaccination.
  • Use of any or non-registered drug or vaccine other than IMVAMUNE® within 30 days preceding the first vaccine dose.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    IMVAMUNE®

    Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals

    Biological: IMVAMUNE®

Interventions

  • BiologicalIMVAMUNE®

    IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose

06

What researchers measure

Primary outcomes

  1. ELISA Seropositivity Rate

    Seropositivity rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seropositivity is defined as antibody titers ≥ detection limit (50). Percentages based on number of subjects with data available.

    Time frame: up to Week 7

Secondary outcomes

  1. ELISA Seroconversion Rate

    Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to the Screening titer for initially seropositive subjects. Percentages based on number of subjects with data available.

    Time frame: Week 7

  2. ELISA GMT

    Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.

    Time frame: up to Week 7

  3. Serious Adverse Events

    Incidence, relationship and intensity of any Serious Adverse Event (SAE).

    Time frame: up to 32 weeks

  4. Related Grade >=3 Adverse Events

    Incidence of any Grade \>=3 Adverse Events possibly, probably or definitely related to the trial vaccine

    Time frame: within 29 days after any vaccination

  5. Non-serious AEs

    Incidence of non-serious AEs

    Time frame: within 29 days after any vaccination

07

Results

Posted Aug 19, 2020

Participant flow

Participant flow — Overall Study
MilestoneMVA-BN
Started22
Completed18
Not completed4
Withdrew: Lost to follow-up4

Outcome measures

PrimaryELISA Seropositivity Rate

Seropositivity rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seropositivity is defined as antibody titers ≥ detection limit (50). Percentages based on number of subjects with data available.

Time frame:
up to Week 7
Reported as:
Number · percentage of subjects
ELISA Seropositivity Rate
percentage of subjectsMVA-BN
Screening40.9 (20.7 to 63.7)
Week 7100.0 (84.6 to 100.0)
SecondaryELISA Seroconversion Rate

Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to the Screening titer for initially seropositive subjects. Percentages based on number of subjects with data available.

Time frame:
Week 7
Reported as:
Number · percentage of subjects
ELISA Seroconversion Rate
percentage of subjectsMVA-BN
ELISA Seroconversion Rate90.9 (70.8 to 98.9)
SecondaryELISA GMT

Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.

Time frame:
up to Week 7
Reported as:
Geometric mean · Titer
ELISA GMT
TiterMVA-BN
Screening370.08 (166.3 to 823.5)
Week 714961.54 (11163.8 to 20051.1)
SecondarySerious Adverse Events

Incidence, relationship and intensity of any Serious Adverse Event (SAE).

Time frame:
up to 32 weeks
Reported as:
Count of participants · Participants
Serious Adverse Events
ParticipantsMVA-BN
Serious Adverse Events0
SecondaryRelated Grade >=3 Adverse Events

Incidence of any Grade \>=3 Adverse Events possibly, probably or definitely related to the trial vaccine

Time frame:
within 29 days after any vaccination
Reported as:
Count of participants · Participants
Related Grade >=3 Adverse Events
ParticipantsMVA-BN
Related Grade >=3 Adverse Events1
SecondaryNon-serious AEs

Incidence of non-serious AEs

Time frame:
within 29 days after any vaccination
Reported as:
Count of participants · Participants
Non-serious AEs
ParticipantsMVA-BN
Non-serious AEs19

Adverse events

Collected over up to 32 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MVA-BN0/22 (0%)0/22 (0%)19/22 (86.4%)
Most frequent other events
Most frequent other events
EventMVA-BN
Injection site painGeneral disorders15/22
Injection site erythemaGeneral disorders8/22
Injection site swellingGeneral disorders8/22
Injection site indurationGeneral disorders6/22
FatigueGeneral disorders4/22
Injection site pruritisGeneral disorders4/22
HeadacheNervous system disorders4/22
MyalgiaMusculoskeletal and connective tissue disorders2/22

Baseline characteristics

Full Analysis Set

Age, Continuous
Age, Continuous(years)MVA-BN
Mean34.36 ± 8.83
Sex: Female, Male
Sex: Female, Male(Participants)MVA-BN
Female10
Male12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MVA-BN
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American1
White14
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)MVA-BN
United States22
08

Study locations

1 site
  • Palo Alto Medical Foundation
    Palo Alto, California 94301, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2010 to primary completion in Nov 2014, 54 months.

Results were first posted in Aug 2020, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2018
First posted
Mar 21, 2018
StartActual
Apr 22, 2010
Primary completionActual
Nov 14, 2014
CompletionActual
Nov 14, 2014
Results first posted
Aug 19, 2020
Last update
Aug 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03472014
Lead sponsor
Bavarian Nordic
Responsible party
Sponsor
First posted
Mar 21, 2018
Start date
Apr 22, 2010
Primary completion
Nov 14, 2014
Completion
Nov 14, 2014
Results posted
Aug 19, 2020
Last update
Aug 19, 2020

Study contacts

Gary Fujimoto, MD
principal investigator · Palo Alto Medical Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-BN smallpox vaccine

Start the discussion